Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients

doi:10.3748/wjg.v27.i42.7340

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 42

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7351)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

523

WORD

154

HTML

4670

Figures (1-4)

291

Sum=5638

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

487

Download

1219

Sum=1706

Nov 14, 2021 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (40)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Nov 14, 2021; 27(42): 7340-7349
Published online Nov 14, 2021. doi: 10.3748/wjg.v27.i42.7340

Full Size Figure Download Figure

Figure 1 Alpha diversity indices (Shannon index) of hepatocellular carcinoma patients based on treatment and prognosis. A: The Shannon index of the non-responders on admission (T0) was not significantly lower than that of the responders (P = 0.14); B: The Shannon index of the non-responders was significantly lower than that of the responders after nivolumab therapy (T1); C: Nivolumab therapy did not alter the Shannon index. HCC: Hepatocellular carcinoma.

Citation: Chung MW, Kim MJ, Won EJ, Lee YJ, Yun YW, Cho SB, Joo YE, Hwang JE, Bae WK, Chung IJ, Shin MG, Shin JH. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients. World J Gastroenterol 2021; 27(42): 7340-7349
URL: https://www.wjgnet.com/1007-9327/full/v27/i42/7340.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i42.7340